(Q36628026)

15 August 2017

1 reference

title

Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? (English)

1 reference

15 August 2017

0 references

Honghui Zhou

1

1 reference

15 August 2017

publication date

1 November 2006

1 reference

The Journal of Clinical Pharmacology

15 August 2017

published in

1 reference

15 August 2017

volume

46

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1268-1289

1 reference

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Potential interaction between telithromycin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Verapamil toxicity resulting from a probable interaction with telithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Acute seizures due to a probable interaction between valproic acid and meropenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Acute myopathy in a patient with concomitant use of pravastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Dextromethorphan-induced delirium and possible methadone interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Supratherapeutic response to ezetimibe administered with cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Capecitabine-warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Possible warfarin interaction with menthol cough drops

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Carbamazepine--indinavir interaction causes antiretroviral therapy failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Acute colchicine intoxication during clarithromycin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Rhabdomyolysis in association with simvastatin and amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Probable ischemic colitis caused by pseudoephedrine with tramadol as a possible contributing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Hypotension due to interaction between lisinopril and tizanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Lithium intoxication as a result of an interaction with rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Orlistat enhances warfarin effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Possible warfarin failure due to interaction with smokeless tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Torsade de pointes induced by cisapride/clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

An incremental method for the study of the absorption of drugs whose kinetics are described by a two-compartment model: estimation of the microscopic rate constants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Smoking and body weight influence the clearance of chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Carbamazepine population pharmacokinetics in children: mixed-effect models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of teicoplanin in patients with endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Non-steady state analysis of the pharmacokinetic interaction between propofol and remifentanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Clinical and pharmacokinetic observations on sodium valproate - a 5-year follow-up study in 100 children with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Comparison of some practical sampling strategies for population pharmacokinetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

High variability of plasma drug concentrations in dual protease inhibitor regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of racemic warfarin in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Physiological Approaches to the Prediction of Drug-Drug Interactions in Study Populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Determination of phenobarbitone population clearance values for South African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Pharmacokinetics of zidovudine in infants: a population analysis across studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of tirilazad: effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of carbamazepine in Singapore epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of tacrolimus in adult kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Pharmacokinetic drug interactions in children taking oxcarbazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294278

21 January 2018

Identifiers

DOI

10.1177/0091270006294278

1 reference

15 August 2017

1 reference